Patented three times more potent formulation of S-adenosylmethionine (SAM-e) further deepens the company’s pipeline
NEW YORK, April 20, 2022 /PRNewswire/ — Bonafide®, the women’s healthcare company that’s pioneering a new, more natural approach to managing menopause symptoms with evidence-based, over-the-counter medical products, announced today. acquisition of a patented and improved formulation of S-adenosylmethionine (SAM-e), with triple the bioavailability of competing products. This acquisition increases Bonafide’s patent holdings to more than 50 issued and pending patents that it owns or exclusively licenses and illustrates its strategy of bringing innovative R&D to the field of women’s health.
SAM-e is a natural substance that is a key nutrient widely used by the body. The SAMe composition, called MSI-195, is a high bioavailability formulation of the dietary ingredient SAM-e, which is primarily used as a dietary supplement to support mood, joint health, and liver function. As part of this acquisition, Bonafide owns all worldwide assets and patents related to the supplement.
Jim KomorowskiBonafide’s Chief Scientific Officer said, “This unique and potent form of SAM-e has been investigated as a potential pharmaceutical product over the past decade with a significant amount of safety, preclinical and clinical research supporting the increased bioavailability of this compound. We are very excited about MSI-195 as it has the potential to help women in a number of important areas, including mood. This technology will be added to Bonafide’s already strong pipeline which includes products for overactive bladder, sleep and other critical symptoms. to women’s health.”
With food supplements market should reach $128 billion by 2028, the demand for quality and efficient products is expected to drive this growth in the years to come.
Bonafide’s commitment to identifying and studying natural products that target the same mechanistic pathways as pharmaceutical drugs is supported by the company’s multi-million dollar investments each year in technology and clinical trials. Bonafide’s portfolio of proprietary, patented ingredients and products establishes a strong scientific foundation for its work with physicians to develop natural solutions for common patient needs. With the completion of this acquisition, Bonafide plans to continue rigorous clinical trials to leverage the patented ingredient in future Bonafide products.
Alyssa DweckMD, Bonafide’s Chief Medical Officer said, “In my more than 25 years of practice as an OB-GYN, I have found that women want and need natural, non-drug alternatives for treating symptoms of hormonal changes during menopause Bonafide is not only bringing unique and naturally powerful products to market, but also leveraging its nationwide team of physician educators to bring this important information directly to traditional physicians and other health care providers. In fact, Bonafide regularly interacts with more than 11,000 health care providers, including many of the top menopause specialists in the United States.”
Since launching in 2018, Bonafide has expanded its product line to include five natural menopausal symptom relief solutions, in addition to a line of best-selling daily essential vitamins. Today, Bonafide has over 120,000 active customers and a monthly customer retention rate of 92%, making Bonafide one of the leading developers of women’s menopause products.
For more information on Bonafide, visit hellobonafide.com.
Bonafide Health was launched with a simple mission in mind: to provide women with innovative, safe and highly effective treatment options to relieve symptoms throughout their journey through menopause. As part of Bonafide’s scientific research and product development process, the brand prides itself on its deep understanding of the biological and physiological changes that affect women due to hormonal fluctuations experienced as they age. Trusted by over 11,000 healthcare professionals, Bonafide offers unique, evidence-based solutions developed using naturally derived ingredients, free of hormones and drugs.
SOURCE Health Bonafide